Navigation Links
International network to study the causes behind IBS
Date:1/28/2013

Europe-wide network GENIEUR including researchers from Sahlgrenska Academy, University of Gothenburg, Sweden, and Karolinska Institutet, Sweden, launch program for understanding the causes and improving the diagnosis and treatment of irritable bowel syndrome

For the first time, scientists from 19 European countries have joined forces to form an interdisciplinary network for investigating the causes of irritable bowel syndrome (IBS), in the hope to improve its diagnosis and treatment.

The European Science Foundation funded network GENIEUR (Genes in Irritable Bowel Syndrome Europe) aims to identify genes and DNA variants that may contribute to increase one's susceptibility to develop bowel symptoms.

Today, IBS affects more than 10 percent of the general population in Sweden, and is the most common cause of work absenteeism after common colds. Its diagnosis is based on a combination of symptoms including abdominal pain, bloating, constipation, and diarrhea, which all strongly impact patients' quality of life. Because of the unknown etiology there is currently no cure, and remedies can only alleviate symptoms and are effective in some patients but not in others.

Over 70 research groups participate in the GENIEUR network, which is headed by Dr Beate Niesler at Heidelberg University Hospital's Institute of Human Genetics, and includes research teams from the Sahlgrenska Academy, University of Gothenburg and Karolinska Institutet.

"Our goal is to use the knowledge of researchers with different expertise in order to solve the mystery of IBS", says Professor Magnus Simren, from the Department of Internal Medicine and Clinical Nutrition at the Sahlgrenska Academy, University of Gothenburg, who is also co-Chair of the GENIEUR initiative and head of a research group focusing on mechanisms underlying the symptoms of IBS.

"IBS is only modestly inherited, and there are so far very few examples of known predisposing genes" adds docent Mauro D'Amato from Karolinska Institutet's Department of Biosciences and Nutrition, member of the GENIEUR management committee and leader of the team who discovered the involvement of TNFSF15 and NPSR1 genes in IBS.

"We need very large numbers of thoroughly-characterized patients in order to increase our chances to detect true genetic predisposing factors".

For this purpose, the teams in GENIEUR aim to establish a large IBS biobank of clinical material from patients and healthy controls.

In so doing, they are also aiming to identify reliable biomarkers and compile a catalogue of criteria to precisely assign patients to individual clinical subgroups.

Besides gastroenterologists and human geneticists, the network also includes nutritionists, psychiatrists, immunologists, physiologists, neurobiologists, microbiologists, bioinformatic specialists and epidemiologists.

"With this broad knowledge included, the potential to achieve clinically important discoveries for this large group of patients is tremendous" says Prof Simren. More information is available at www.genieur.eu.


'/>"/>
Contact: Magnus Simren
magnus.simren@medicine.gu.se
University of Gothenburg
Source:Eurekalert

Related medicine news :

1. GeneCell International and its Subsidiary Celulas Madre Latin America Opens State-of-the-Art Clinical Laboratory, BIOCEMA, to Serve Thousands of Families in Venezuela
2. At least 1 in 5 were infected in flu pandemic, international study suggests
3. Xocai's New Xe Product Provides An Incentive For Marketing Xocolate International Corporation (MXI Corp) Distributors To Launch Their Business To A Whole New Level
4. TekLink International Inc. Announces 30% Increase in Revenue for 2012
5. A Delicious, And Healthy New Seasonal Hot Chocolate Beverage, Xocai's Sipping Xocolate, Has Been Released By Marketing Xocolate International Corporation (MXI Corp)
6. Natural Source International Introduces New 'Recipe For Health'
7. AkAsha International Launches Children's Book Series
8. The Leader In Healthy Chocolate; Marketing Xocolate International Corporation (MXI Corp) Expands Their Operations To Hong Kong, Xocai Now Available On Five Continents
9. Law Firm of Garcia & Phan Settles Another "Pre-litigation Settlement" for Online Trademark/Copyright Infringement on Behalf of their Client CortiSLIM® International
10. Benefit Specialists Deems International Health Insurance a Must-Have for Spring Vacations
11. ASH international clinical collaboration replicates high cure rate of APL in developing countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... FL (PRWEB) , ... February 23, 2017 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – will return to the La Gorce Country Club in Miami Beach to ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss ... WE TV’s “Mama June: From Not to Hot,” which will begin airing on February ... Shannon, known to millions from the 2012 reality television series, “Here Comes Honey Boo ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO ... the National Institute for Health and Care Excellence (NICE) framework. The ... National Health Service (NHS) to search, order and purchase medical and healthcare-related content ...
(Date:2/23/2017)... ... 2017 , ... Pink Pig Publishing LLC announces the launch ... the world from different perspectives. By providing a place for people of all ... empathy, and find greater happiness. , "Our approach to structuring content is ...
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... the pre-eminent publication and community for those in the fight against cancer, has ... important in their success. HRA will release top-line findings in a webinar, ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 23, 2017 Non-alcoholic ... on the various drugs being developed for ... all the drugs that are in various ... The pipeline focuses on novel pharmacologic drugs ... stem cell therapies, recombinant proteins and RNA-based ...
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., ... announced that it has acquired exclusive worldwide rights ... best-in-class innovative HDAC inhibitor targeting hematological and solid ... 14 Phase 1 and 2 clinical trials of ... have already been completed, demonstrating that ...
(Date:2/23/2017)... DUBLIN , Feb 23, 2017 Research ... Disorder Drugs Price Analysis and Strategies - 2016" report to ... ... - 2016, provides drug pricing data and benchmarks in the global ... What are the key drugs marketed ...
Breaking Medicine Technology: